menu
    • menu

    Company profile for HilleVax

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Advancing the development of a vaccine to protect against norovirus infection, the most common viral cause of acute gastroenteritis worldwide.HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovir...
    Advancing the development of a vaccine to protect against norovirus infection, the most common viral cause of acute gastroenteritis worldwide.HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HilleVaxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    75 State St, Suite 100 Boston, MA 02109
    Telephone
    Telephone
    (888) 340-4544
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hillevax.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/hillevax
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/HilleVax

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    XOMA Royalty Announces Tender Offer Closure for HilleVax
    XOMA Royalty Announces Tender Offer Closure for HilleVax

    17 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/17/3151655/7281/en/XOMA-Royalty-Announces-Closing-of-Tender-Offer-for-HilleVax-Inc.html

    GLOBENEWSWIRE
    17 Sep 2025
    Share Share
    HilleVax Reports Second Quarter 2025 Financial Results
    HilleVax Reports Second Quarter 2025 Financial Results

    06 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/06/3128672/0/en/HilleVax-Reports-Second-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    06 Aug 2025
    Share Share
    HilleVax Enter into a Definitive Agreement to be Acquired by XOMA
    HilleVax Enter into a Definitive Agreement to be Acquired by XOMA

    05 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/04/3126426/0/en/HilleVax-Enters-into-a-Definitive-Agreement-to-be-Acquired-by-XOMA-Royalty-for-1-95-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html

    GLOBENEWSWIRE
    05 Aug 2025
    Share Share
    HilleVax Enter into a Definitive Agreement to be Acquired by XOMA
    HilleVax Enter into a Definitive Agreement to be Acquired by XOMA

    04 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/04/3126426/0/en/HilleVax-Enters-into-a-Definitive-Agreement-to-be-Acquired-by-XOMA-Royalty-for-1-95-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html

    GLOBENEWSWIRE
    04 Aug 2025
    Share Share
    HilleVax Reports Q1 2025 Financial Results and Recent Progress
    HilleVax Reports Q1 2025 Financial Results and Recent Progress

    08 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/08/3077088/0/en/HilleVax-Reports-First-Quarter-2025-Financial-Results-and-Highlights-Recent-Company-Progress.html

    GLOBENEWSWIRE
    08 May 2025
    Share Share
    HilleVax Reports 2024 Financial Results and Company Progress
    HilleVax Reports 2024 Financial Results and Company Progress

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051660/0/en/HilleVax-Reports-Full-Year-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search